Logo image of IMNM

IMMUNOME INC (IMNM) Stock Fundamental Analysis

NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD

8.85  -0.01 (-0.11%)

After market: 8.85 0 (0%)

Fundamental Rating

3

IMNM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. IMNM has a great financial health rating, but its profitability evaluates not so good. IMNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMNM had negative earnings in the past year.
In the past year IMNM has reported a negative cash flow from operations.
IMNM had negative earnings in each of the past 5 years.
IMNM had a negative operating cash flow in each of the past 5 years.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -121.95%, IMNM is doing worse than 80.39% of the companies in the same industry.
Looking at the Return On Equity, with a value of -161.71%, IMNM is doing worse than 65.19% of the companies in the same industry.
Industry RankSector Rank
ROA -121.95%
ROE -161.71%
ROIC N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

IMNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNM has more shares outstanding
The number of shares outstanding for IMNM has been increased compared to 5 years ago.
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 3.58 indicates that IMNM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.58, IMNM is in the better half of the industry, outperforming 77.39% of the companies in the same industry.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.58
ROIC/WACCN/A
WACC10.04%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.08 indicates that IMNM has no problem at all paying its short term obligations.
The Current ratio of IMNM (4.08) is comparable to the rest of the industry.
A Quick Ratio of 4.08 indicates that IMNM has no problem at all paying its short term obligations.
IMNM has a Quick ratio (4.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

IMNM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -55.16%.
The Revenue for IMNM has decreased by -35.50% in the past year. This is quite bad
EPS 1Y (TTM)-55.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
Revenue 1Y (TTM)-35.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-28.44%

3.2 Future

IMNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.56% yearly.
Based on estimates for the next years, IMNM will show a very strong growth in Revenue. The Revenue will grow by 100.97% on average per year.
EPS Next Y44.25%
EPS Next 2Y18.36%
EPS Next 3Y13.24%
EPS Next 5Y15.56%
Revenue Next Year-86.35%
Revenue Next 2Y36.22%
Revenue Next 3Y99.63%
Revenue Next 5Y100.97%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMNM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as IMNM's earnings are expected to grow with 13.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.36%
EPS Next 3Y13.24%

More info and screens

0

5. Dividend

5.1 Amount

IMNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOME INC

NASDAQ:IMNM (5/2/2025, 8:02:14 PM)

After market: 8.85 0 (0%)

8.85

-0.01 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners63.03%
Inst Owner Change0.12%
Ins Owners1.68%
Ins Owner Change12.24%
Market Cap770.04M
Analysts86.67
Price Target24.14 (172.77%)
Short Float %17.14%
Short Ratio11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-76.88%
Min EPS beat(2)-116.8%
Max EPS beat(2)-36.96%
EPS beat(4)0
Avg EPS beat(4)-107.64%
Min EPS beat(4)-254.68%
Max EPS beat(4)-22.13%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)9.39%
Min Revenue beat(2)-14.94%
Max Revenue beat(2)33.73%
Revenue beat(4)1
Avg Revenue beat(4)-13.57%
Min Revenue beat(4)-63.97%
Max Revenue beat(4)33.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.17%
PT rev (3m)-21.11%
EPS NQ rev (1m)1.29%
EPS NQ rev (3m)9.48%
EPS NY rev (1m)-8.45%
EPS NY rev (3m)7.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-58.51%
Revenue NY rev (3m)-58.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 85.11
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-5.06
EYN/A
EPS(NY)-2.82
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0.1
BVpS2.08
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.95%
ROE -161.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3414.68%
Cap/Sales 591.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z 3.58
F-Score2
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)1218.68%
Cap/Depr(5y)748.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
EPS Next Y44.25%
EPS Next 2Y18.36%
EPS Next 3Y13.24%
EPS Next 5Y15.56%
Revenue 1Y (TTM)-35.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-28.44%
Revenue Next Year-86.35%
Revenue Next 2Y36.22%
Revenue Next 3Y99.63%
Revenue Next 5Y100.97%
EBIT growth 1Y-434.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1856.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1363.98%
OCF growth 3YN/A
OCF growth 5YN/A